← DPP-4 inhibitors × hypoglycaemia

Observational studyCardiovascular diabetology2016

Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.

Huang-Tz Ou et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2016

Randomised comparison

Probably raised hypoglycaemia

+30%+20% to +43%

Bigger than 5 in 10 on the map

As reported

HR 1.3, 95% CI 1.20–1.43

Not counted

Probably raised glycemic control

3.7×3.4× to 4.1×

Bigger than 8 in 10 for glycemic control

As reported

HR 3.73, 95% CI 3.35–4.14

Not counted

Probably lowered hypoglycaemia

−13%−21% to −6%

Bigger than 3 in 10 on the map

As reported

HR 0.87, 95% CI 0.79–0.94

Three numbers in the abstract

the abstract, start to end

… to DPP4i users, meglitinides (aHR 1.3, 95 % CI 1.20-1.43) and insulin users (aHR 3.73, 95 % CI 3.35, 4.14) had …

… lower risks for composite CVD risk (aHR 0.87, 95 % CI 0.79-0.94), as well as …

← favours treatmentfavours comparator →
could be chance
Hypoglycaemia
HR 1.31.20–1.43
Glycemic control
HR 3.733.35–4.14
Hypoglycaemia
HR 0.870.79–0.94
MetforminDPP-4 inhibitorsGlycemic controlHypoglycaemia
1 / 4

41 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 26932742